Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients (Q51558091)

7 April 2018

title

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients (English)

1 reference

7 April 2018

0 references

1 reference

Bruce H Wolffenbuttel

1 reference

7 April 2018

author name string

Gomis R

1 reference

7 April 2018

Squatrito S

1 reference

7 April 2018

Jones NP

1 reference

7 April 2018

Patwardhan RN

1 reference

7 April 2018

publication date

1 January 2000

1 reference

7 April 2018

published in

Diabetic Medicine

1 reference

7 April 2018

volume

1 reference

7 April 2018

issue

1 reference

7 April 2018

page(s)

40-47

1 reference

7 April 2018

Pathogenesis of NIDDM. A balanced overview

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

A novel antidiabetic drug, troglitazone--reason for hope and concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

The effect of leptin is enhanced by microinjection into the ventromedial hypothalamus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Prospective Study of Small LDLs as a Risk Factor for Non–Insulin Dependent Diabetes Mellitus in Elderly Men and Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Thiazolidinediones: a new class of antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Prospective Study of Serum -Glutamyltransferase and Risk of NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

Section Review: Oncologic, Endocrine & Metabolic: Thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2000.00224.X

10.1046/J.1464-5491.2000.00224.X

21 January 2018

Identifiers

DOI

1 reference

7 April 2018

1 reference

7 April 2018